Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison

Archives of General Psychiatry

Volumn 53, Issue 12, 1996, Pages 1090-1097

  Kumra, Sanjiv ^a   Frazier, Jean A ^b   Jacobsen, Leslie K ^a   McKenna, Kathleen ^c   Gordon, Charles T ^d   Lenane, Marge C ^a   Hamburger, Susan D ^a   Smith, Amy K ^a   Albus, Kathleen E ^a   Alaghband Rad, Javad ^a   Rapoport, Judith L ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZATROPINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ADOLESCENT; ARTICLE; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERSALIVATION; INSOMNIA; LIVER TOXICITY; MALE; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; ONSET AGE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; SEIZURE;

EID: 10544235439     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1996.01830120020005     Document Type: Article

References (68)

1. McClellan J, Werry J. Practice parameters for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 1994;33:616-635.
2. Asarnow J, Tompson M, Goldstein M. Childhood-onset schizophrenia: a follow-up study. Schizophr Bull. 1994;20:599-617.
3. Green W, Gayol M, Hardesty A, Bassiri M. Schizophrenia with childhood onset: a phenomenological study of 38 cases. J Am Acad Child Adolesc Psychiatry. 1992;31:968-976.
4. Alaghaband-Rad J, McKenna K, Gordon C, Albus K, Hamburger S, Rumsey J, Frazier J, Lenane M, Rapoport J. Childhood-onset schizophrenia: the severity of premorbid course. J Am Acad Child Adolesc Psychiatry. 1995;34:1273-1283.
5. Gordon C, Frazier J, McKenna K, Giedd J, Zametkin A, Zahn T. Hommer D, Hong W, Kaysen D, Albus K, Rapoport J. Childhood-onset schizophrenia: an NIMH study in progress. Schizophr Bull. 1994;20:697-712.
6. Campbell M, Spencer E. Psychopharmacology in child and adolescent psychiatry: a review of the past five years. J Am Acad Child Adolesc Psychiatry. 1988;27:269-279.
7. Realmuto GM, Erickson WD, Yellin AM, Hopwood JH, Greenberg LM. Clinical comparison of thiothixene and thiondazine in schizophrenic adolescents. Am J Psychiatry. 1984;141:440-442.
8. Keepers G, Clappison V, Casey D. Initial anticholinergic prophylaxis for acute neuroleptic induced extrapyramidal syndromes. Arch Gen Psychiatry. 1983; 40:1113-1117.
9. Pool D, Bloom W, Mielke DH, Roniger JJ, Gallant DM. A controlled evaluation of loxitane in 75 adolescent schizophrenic patients. Curr Ther Res. 1976;19:99-104.
10. Spencer EK, Kafantaris V, Padron-Gayol MV, Rosenberg CR, Campbell M. Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull. 1992;28:183-186.
11. Spencer EK, Campbell M. Children with schizophrenia: diagnosis, phenomenology and pharmacotherapy. Schizophr Bull. 1994;20:713-725.
12. Carpenter WT, Conley RR, Buchanan RW, Breier A, Tamminga CA. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry. 1995;152:827-832.
13. Schmidt M, Trott G, Blanz B, Nissen G. Clozapine medication in adolescents. In: Stefanis C, Rabavilas A, Soldatos C, eds. Psychiatry: A World Perspective. Proceedings of the VIII World Congress of Psychiatry. Belle Mead, NJ: Excerpta Medica-Princeton; 1989;1:1100-1104.
14. Remschmidt H, Schulz E, Martin M. An open trial of clozapine in 36 adolescents with schizophrenia. J Child Adolesc Psychopharmacol 1994;4:31-41.
15. Frazier JA, Gordon CT, McKenna K, Lenane MC, Jih D, Rapoport JL. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry. 1994;33:658-663.
16. McKenna K, Gordon C, Lenane M, Kaysen D, Fahey K, Rapoport J. Looking for childhood-onset schizophrenia: the first 71 cases screened. J Am Acad Child Adolesc Psychiatry. 1994;33:636-644.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
18. Orvaschell H, Tabrizi M, Chambers W. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Epidemiologic Version (Kiddie-SADSE). Philadelphia: Medical College of Pennsylvania. Eastern Pennsylvania Psychiatric Institute; 1987.
19. Reich W, Welner Z. DICA-RC (DSM-III-R Version). St Louis, Mo: Washington University; 1988.
20. Overall JE, Gorham DE. The Brief Psychiatric Rating Scale. Psychol Rep 1961; 10:799-812
21. Bunney WE, Hamburg DA. Methods for reliable longitudinal observation of behavior. Arch Gen Psychiatry. 1963;9:280-294.
22. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S A Children's Global Assessment Scale (CGAS). Arch Gen Psychiatry. 1983;40:1228-123.
23. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: US Dept of Health and Human Services; 1976
24. Overall J, Pfefferbaum B. A Brief Psychiatric Rating Scale for Children. Innovations. 1984;3:264.
25. Andreasen NC. The Scale for the Assessment of Positive Symptoms, (SAPS). Iowa City: The University of Iowa; 1984.
26. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City: The University of Iowa; 1983.
27. Campbell M, Palig M. Subjective Treatment Emergent Symptoms Scale (STESS). Psychopharmacol Bull. 1985;21:1063-1082.
28. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
29. Rapoport J, Connors C, Reatig N. Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharm Bull. 1985; 21:713-1111.
30. Simpson G, Angus J. A rating scale for extrapyramidal side effects Acta Psychiatr Scand. 1970;(suppl 212):9-11.
31. SAS Institute. SAS Language and Procedures: Usage, Version 6, First Edition. Cary, NC: SAS Institute Inc; 1989.
32. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. N Engl J Med. 1993;329:162-167.
33. Yang PC, Liu CY, Chiang SQ, Chen JY, Lin TS. Comparison of adult manifestations of schizophrenia with onset before and after 15 years of age Acta Psychiatr Scand. 1995;91:209-212.
34. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapoport MH. Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry. 1992;49:345-353.
35. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D. Summerfelt A. Carpenter WT. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 1994;151:20-26.
36. Jacobsen L, Walker M, Edwards J, Chappell P, Woolston J. Clozapine in the treatment of a young adolescent with schizophrenia J Am Acad Child Adolesc Psychiatry. 1994;33:645-650.
37. Birmaher B, Baker R, Kaput S, Quintana M, Ganguli R. Clozapine for the treatment of adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 1991;31:160-164.
38. Meltzer HY. Treatment of the neuroleptic nonresponsive schizophrenic patient, Schizophr Bull. 1992;18:515-542.
39. Mozes T, Toren P, Chernauzen N, Mester R, Yoran-Hagesh R, Blumensohn R, Weizman A. Clozapine treatment in very early onset schizophrenia. J Am Acad Child Adolesc Psychiatry. 1994;33:65-70.
40. Towbin KE, Oykens EM, Pugliese RG. Case study Clozapine for early developmental delays with childhood-onset schizophrenia: protocol and 15-month outcome. J Am Acad Child Adolesc Psychiatry. 1994;33:651-658.
41. Remschmidt HE, Schulz E, Martin M, Warnke A, Trott G. Childhood-onset schizophrenia: history of the concept and recent studies. Schizophr Bull. 1994;20:727-745
42. Meltzer HY. Clozapine: is another view valid? Am J Psychiatry. 1995;152:821-825.
43. Kane JM, Schooler N, Marder S, Wirshing W, Ames D, Umbricht D, Safferman A, Baker R, Ganguli R. Efficacy of Clozapine vs haloperidol in a long-term clinical trial. Schizophr Res. 1996;18:127. Abstract.
44. Gerson SL. Clozapine: deciphering the risks. N Engl J Med. 1993;329:204-205.
45. Piscitelli SC, Frazier JA, McKenna K, Albus KE, Grothe DR, Gordon CT. Rapoport JL Plasma Clozapine and halopericol concentrations in adolescents with childhood-onset schizophrenia: association with response J Clin Psychiatry. 1994;55:94-97.
46. Gerson SL, Arce C, Meltzer HY. N-desmethyclozapine: a Clozapine metabolite that suppresses hemapoiesis. Br J Haemotol. 1994;85:123-125.
47. Safferman A, Lieberman J, Alvir J, Howard A. Rechallenge in clozapine-induced agranulocytosis. Lancet. 1992;339:1296-1297.
48. Krassner M. Sandoz Pharmaceutical Corporation Brochure on Possible Drug Interactions With Clozapine East Hanover, NJ: Pharmaceutical Safety Division, Sandoz Pharmaceutical Corp; 1995
49. Freedman J, Wirshing W, Russell A, Bray M, Unutzer J. Absence status seizures during successful long-term clozapine treatment of an adolescent with schizophrenia. J Child Adolesc Psychopharmacol. 1994;4:53-62
50. Devinsky O, Pacia S. Seizures during clozapine therapy, J Clin Psychiatry. 1994; 55:153-156.
51. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures Neurology. 1991; 41:369-371.
52. Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5629 patients. Neurology. 1994;44:2247-2249.
53. Welch J, Manschreck T, Redmond D. Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neurosci. 1994;6:250-256.
54. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry. 1992;149:68-72.
55. Umbricht D, Pollack S Kane J. Clozapine and weight gain. J Clin Psychiatry. 1994;55(suppl B, part 9):157-160.
56. Campbell A, Baldessarini RJ, Teicher MH. Decreasing sensitivity to neuroleptic agents in developing rats: evidence for a pharmacodynamic factor. Psychopharmacology. 1988;94:46-51.
57. Baldessarini RJ, Teicher MH. Dosing of antipsychotic agents in pediatric populations. J Child Adolesc Psychopharmacol. 1995;5:1-4.
58. Mandoki M. Risperidone treatment of children and adolescents: increased risk of extrapyramidal side effects? J Child Adolesc Psychopharmacol. 1995;5:49-67.
59. Zahn T, Jacobsen L, Gordon C, McKenna K, Frazier JA, Rapoport J. Autonomic nervous system markers of psychopathology in childhood-onset schizophrenia. Arch Gen Psychiatry. In press.
60. Jacobsen L, Hong W, Hommer D, Frazier J, Giedd J, Gordon C, Karp B, McKenna K, Rapoport J. Smooth pursuit eye movements in childhood-onset schizophrenia: comparison with ADHD and normal controls. Biol Psychiatry. In press.
61. Frazier J, Giedd J, Hamburger S, Albus K, Kaysen D, Vaituzis A, Rajapaske J, Lenane H, McKenna K, Jacobsen L, Gordon C, Breier A, Rapoport J. Brain anatomic magnetic resonance imaging in childhood-onset schizophrenia. Arch Gen Psychiatry. 1996;53:617-624.
62. Hafner H, Nowotny B. Epidemiology of early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 1995;245:80-92.
63. Benes M, Turtle M, Khan Y, Farol P. Myelination of a key relay zone in the hippocampal formation occurs in the human brain during childhood, adolescence, and adulthood Arch Gen Psychiatry. 1994;51:477-484.
64. Breier A, Schreiber J, Dyer J, Pickar D. National Institute of Mental Health Longitudinal Study of Chronic Schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry. 1991;48:239-246.
65. Levkovitch Y, Kronenberg J, Kayser N, Zvyvagelski M, Gaoni B, Gadoth N. Clozapine for tardive dyskinesia in adolescents. Brain Dev. 1995;17:213-215.
66. Gualtieri C, Quade D, Hicks R, Mayo J, Schroeder S. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am J Psychiatry. 1984;141:20-23.
67. Casey D. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl). 1989;99(suppl):47-53.
68. Kane J, Woemer M, Pollack S, Safferman A, Lieberman J. Does Clozapine cause tardive dyskinesia? J Clin Psychiatry. 1993;54:327-330.